EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 24 IN BIOLOGIC EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SUMMARY RESULTS

被引：0
|
作者：
Marzo-Ortega, Helena [1 ,2 ]
Meroni, Pierluigi [3 ]
Galindez-Agirregoikoa, Eva [4 ]
Behrens, Frank [5 ,6 ]
Bradley, Andrew J. [7 ]
Leage, Soyi Liu [7 ]
Garcia, Miriam [7 ]
Sapin, Christophe [7 ]
Ho, Ji Chen [8 ]
Constantin, Arnaud [9 ]
Hall, Stephen [10 ]
机构：
[1] Univ Leeds, Leeds Teaching Hosp Trust, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England
[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[3] Univ Milan, Ist Auxol Italiano, Milan, Italy
[4] Univ Hosp Basurto, Serv Reumatol, Bilbao, Spain
[5] Goethe Univ Frankfurt, Div Rheumatol, Frankfurt, Germany
[6] Goethe Univ Frankfurt, IME Fraunhofer Project Grp Translat Med & Pharmac, Frankfurt, Germany
[7] Eli Lilly & Co, Lilly Int, Indianapolis, IN 46285 USA
[8] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan
[9] Hosp Pierre Paul Riquet, Dept Rheumatol, Toulouse, France
[10] Monash Univ, Dept Med, Clayton, Vic, Australia
来源：
RHEUMATOLOGY | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O03
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 845 - 845
  • [32] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, V.
    Fleischmann, R.
    Lespessailles, E.
    Helliwell, P. S.
    Benichou, O.
    Erickson, J.
    Shuler, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 385 - 385
  • [33] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS
    Boehncke, Wolf Henning
    Gottlieb, Alice
    Deodhar, Atul
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 48 - 49
  • [34] Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-na?ve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
    Reich, Kristian
    Kristensen, Lars Erik
    Smith, Saxon D.
    Rich, Phoebe
    Sapin, Christophe
    Leage, Soyi Liu
    McKenzie, Robert
    Schuster, Christopher
    Riedl, Elisabeth
    Gooderham, Melinda
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2022, 12 (02):
  • [35] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Padilla, Byron
    Kivitz, Alan
    RHEUMATOLOGY, 2023, 62 (06) : 2122 - 2129
  • [36] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    RHEUMATOLOGY, 2023, 62 (06) : 2113 - 2121
  • [37] Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
    Cohen, Stanley
    Fiechtner, Justus
    Mease, Philip
    Kaine, Jeffrey
    Kavanaugh, Arthur
    Cheng, Yi-Lin
    Chou, Claire
    Cheng, Ting-Ying
    Lin, Shih-Yao
    Genovese, Mark
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [38] Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1) (vol 45, pg 367, 2018)
    Van der Heijde, D.
    Gladman, D. D.
    Kishimoto, M.
    Okada, M.
    Rathmann, S. S.
    Moriarty, S. R.
    Shuler, C. L.
    Carlier, H.
    Benichou, O.
    Mease, P. J.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (11) : 1608 - 1608
  • [39] Effect of concomitant conventional disease-modifying antirheumatic drug (cDMARDS) on safety and efficacy of ixekizumab in biologic dmard (bDMARD) naive patients with active psoriatic arthritis (PsA)
    Coates, L. C.
    Gottlieb, A. B.
    Shuler, C. L.
    Lin, C. -Y.
    Samanta, S.
    Moriarty, S. R.
    Lee, C. H.
    Mease, P. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 32 - 32
  • [40] Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naive Patients with Psoriatic Arthritis: 52-Week Results
    Smolen, Josef
    Sebba, Anthony
    Ruderman, Eric
    Gellett, Amanda
    Sapin, Christophe
    Sprabery, Aubrey
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Reis, Paulo
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345